ClinicalTrials.gg
TerminatedNCT04790903Updated Jul 11, 2024

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 1 interventional study of Venetoclax and Polatuzumab Vedotin in Lymphoma, Large B-Cell, Diffuse, sponsored by Hoffmann-La Roche. Terminated at 20 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was terminated
Decision to discontinue the study based on broader development and strategic prioritisation. The Sponsor concludes there is no benefit-risk impact on the BO42203 study.

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse — 4 open to participants now, 8 under way, 1 of them phase 3. venetoclax · Lymphoma, Large B-Cell, Diffuse.

Enrollment
7th of 17
50 · median 31
Started
2021
with 1 other
Phase 1
6 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
1 of 17
Hoffmann-La Roche

Among the 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse, this one is the 7th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 1, and was the 11th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

4 of the 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing venetoclax in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and pharmacokinetics of venetoclax in combination with Pola + R-CHP in previously untreated participants with BCL-2 IHC-positive DLBCL. Approximately 50 participants will be enrolled in this study in five consecutive cohorts each consisting of approximately 10 participants.

03

Conditions studied

  • Lymphoma, Large B-Cell, Diffuse
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated participants with CD20-positive DLBCL.
  • BCL-2 protein overexpression by IHC, as assessed by local testing.
  • (ECOG) Performance Status of 0, 1, or 2.
  • International Prognostic Index (IPI) 2-5.
  • of more than 6 months.
  • (LVEF) ≥ 50%, as determined on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO).
  • Availability of archival or freshly collected tumor tissue prior to study enrollment.
  • At least one bi-dimensionally fluorodeoxyglucose-avid measurable lymphoma lesion on PET/CT scan, defined as > 1.5 cm in its longest dimension on CT scan.
  • Adequate hematopoietic function.
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use , and agreement to refrain from donating eggs.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of unclassifiable B-cell lymphoma.
  • Prior treatment for indolent lymphoma.
  • Current Grade > 1 peripheral neuropathy.
  • Prior organ transplantation.
  • Prior use of any monoclonal antibody within 3 months and any therapy within 28 days prior to the start of Cycle 1.
  • Vaccination with within 28 days prior to the start of Cycle 1.
  • Prior therapy for DLBCL and High-Grade B-cell Lymphoma (HGBCL) with the exception of palliative, short-term treatment with .
  • Recent major surgery (within 6 weeks prior to the start of Day 1 of Cycle 1), other than for diagnosis.
  • History of other cancers within 2 years prior to screening.
  • Any active infection that, in the opinion of the investigator, would impact participant safety within 7 days prior to Day 1 of Cycle 1.
  • Serious infection requiring oral or IV antibiotics within 4 weeks prior to Day 1 of Cycle 1.
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.
  • Positive test for /C Viruses (HBV/) and Human T-cell Leukemia Virus (HTLV)-1.
  • Known infection with .
  • History of progressive multifocal leukoencephalopathy.
  • Suspected active or latent tuberculosis.
  • history of liver disease, including viral or other hepatitis or cirrhosis.
  • Substance abuse, including non-prescription drug and alcohol dependence, within 12 months prior to screening.
  • Pregnant or breastfeeding, or intending to become pregnant during the study within 6 months after the final dose of venetoclax, 9 months after the final dose of polatuzumab vedotin, or 12 months after the final dose of rituximab.
  • History or presence of an abnormal that is clinically significant in the investigator's opinion.
  • Malabsorption syndrome or other condition that would interfere with enteral absorption.
  • Blood transfusion within 14 days prior to screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Venetoclax (Schedule A)

    Participants enrolled in dosing Schedule A will receive a total of six 21-day cycles of venetoclax treatment for 5 days in combination with Polatuzumab Vedotin + R-CHP (Rituximab, Cyclophosphamide, Doxorubicin and Prednisone) as described below: Schedule A: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 5 consecutive days as follows: Cycle 1: 5 consecutive days of dosing on Days 4-8. Cycles 2-6: 5 consecutive days of dosing on Days 1-5.

    Drug: Venetoclax · Drug: Polatuzumab Vedotin · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone

  • Experimental
    Venetoclax (Schedule B)

    Participants enrolled in dosing Schedule B will receive a total of six 21-day cycles of venetoclax treatment for 10 days in combination with Polatuzumab Vedotin + R-CHP as described below: Schedule B: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 10 consecutive days as follows: Cycle 1: 10 consecutive days of dosing on Days 4-10. Cycles 2-6: 10 consecutive days of dosing on Days 1-10.

    Drug: Venetoclax · Drug: Polatuzumab Vedotin · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone

Interventions

  • Participants will self-administer Venetoclax, as described in the Arm Descriptions.

  • Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.

  • Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.

  • Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.

  • Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.

  • Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Dose-Limiting Toxicities (DLTs)

    Time frame: Cycle 1 Day 1 up to but not including Cycle 3 Day 1 (Cycle length = 21 days)

Secondary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to 4 years

  2. Complete Response (CR) rate at the end of treatment

    Assessed by the investigator on PET and computed tomography (PET/CT) scans according to the Lugano Response Criteria for Malignant Lymphoma (Cheson et al. 2014)

    Time frame: Up to 4 years

  3. Objective Response Rate (ORR) at the end of treatment

    Defined as the proportion of patients with a CR or a partial response (PR), as determined by the investigator on PET/CT scans according to the Lugano 2014 Response Criteria

    Time frame: Up to 4 years

  4. Duration of Response (DOR)

    Defined as the time from the first occurrence of a documented objective response (a PR or a CR) to disease progression, relapse, or death from any cause (whichever occurs first), as determined by the investigator according to the Lugano 2014 Response Criteria

    Time frame: Up to 4 years

  5. Progression-Free Survival (PFS)

    Defined as the time from the date of first study treatment to the first occurrence of disease progression or relapse, as assessed by the investigator, according to the Lugano 2014 Response Criteria, or death from any cause, whichever occurs earlier

    Time frame: Up to 4 years

  6. Plasma Concentrations of Venetoclax at specified timepoints

    Time frame: Up to 4 years

  7. Plasma Concentrations of Polatuzumab Vedotin analytes at specified timepoints

    Time frame: Up to 4 years

07

Study locations

20 sites
  • NYU Langone Hospitals, NYU Langone Rusk Ambulatory Surgical Pharmacy
    New York, New York 10016, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • SARAH CANNON RESEARCH INST.; Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
    Lille, 59037, France
  • CHU Montpellier - Saint ELOI
    Montpellier, 34295, France
  • CHU de Nantes; Cancéro-dermatologie
    Nantes, 44093, France
  • Hôpital Saint-Louis
    Paris, 75475, France
  • Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale
    Pierre Benite, 69310, France
  • CHU Rennes - Hopital Pontchaillou
    Rennes cedex 09, 35033, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica
    Napoli, Campania 80131, Italy
  • Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; Dip. Scienze Mediche e Chirurgiche
    Bologna, Emilia-Romagna 40138, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST; Farmacia Oncologica
    Meldola, Emilia-Romagna 47014, Italy
  • Ospedale Santa Maria Delle Croci
    Ravenna, Emilia-Romagna 48100, Italy
  • Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia
    Pisa, Piemonte 56126, Italy
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital de la Santa Creu i Sant Pau; Servicio de Dermatologia
    Barcelona, 08025, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital General Univ. Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario La Fe; Servicio de Farmacia
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: No — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in May 2024, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 10, 2021
StartActual
Jul 2, 2021
Primary completionActual
May 21, 2024
CompletionActual
May 21, 2024
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04790903
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 10, 2021
Start date
Jul 2, 2021
Primary completion
May 21, 2024
Completion
May 21, 2024
Last update
Jul 11, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Polatuzumab vedotin · Rituximab · Cyclophosphamide · Doxorubicin · Prednisone

Start the discussion